About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Feb 25, 2020...
After investing $26 million in research during the past 15 years, NETRF has helped to establish the NET knowledge base needed to expand the exploration of improved treatments, according to Elyse Gellerman, NETRF Chief Executive Officer. “We can see real momentum in this new round of grants. We hope the discoveries from these projects will lead to improved treatment options for patients.”
NETRF is supporting a new pioneering approach to NET immunotherapy with a Petersen Accelerator Award to Steven Libutti, MD, Rutgers Cancer Institute of New Jersey, to characterize a novel immune regulator called B7x to determine whether it has a role in shutting off the body’s immune response to fight against pancreatic NETs.
Aug 14, 2020... REHOVOT, ISRAEL—August 14, 2020—Something like a quarter of the world’s population suffers from chronic pain at some point. As opposed to acute pain – for example, that feeling after hitting your finger with a hammer – chronic pain may not even have a clear cause, and it can linger for years or lifetimes. The burden of chronic pain includes damage to mental and physical health, lower productivity, and drug addiction. Now, a study led by researchers at the Weizmann Institute of Science suggests an original approach to treating this affliction by targeting a key gateway – one that leads to the activation of genes in the peripheral nerve cells that are involved in many forms of chronic pain. The findings of this study were published in Science.
©2022 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR